Liu Teresa T, Arango-Argoty Gustavo, Li Zhihua, Lin Yuefeng, Kim Sang Woo, Dueck Anne, Ozsolak Fatih, Monaghan A Paula, Meister Gunter, DeFranco Donald B, John Bino
Department of Computational and Systems Biology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15260, USA.
University of Regensburg, Biochemistry I, 93053 Regensburg, Bavaria, Germany.
RNA. 2015 Jun;21(6):1159-72. doi: 10.1261/rna.045559.114. Epub 2015 Apr 22.
The highly conserved, multifunctional YB-1 is a powerful breast cancer prognostic indicator. We report on a pervasive role for YB-1 in which it associates with thousands of nonpolyadenylated short RNAs (shyRNAs) that are further processed into small RNAs (smyRNAs). Many of these RNAs have previously been identified as functional noncoding RNAs (http://www.johnlab.org/YB1). We identified a novel, abundant, 3'-modified short RNA antisense to Dicer1 (Shad1) that colocalizes with YB-1 to P-bodies and stress granules. The expression of Shad1 was shown to correlate with that of YB-1 and whose inhibition leads to an increase in cell proliferation. Additionally, Shad1 influences the expression of additional prognostic markers of cancer progression such as DLX2 and IGFBP2. We propose that the examination of these noncoding RNAs could lead to better understanding of prostate cancer progression.
高度保守的多功能YB-1是一种强大的乳腺癌预后指标。我们报道了YB-1的一种普遍作用,它与数千种非多聚腺苷酸化短RNA(shyRNAs)相关联,这些短RNA会进一步加工成小RNA(smyRNAs)。其中许多RNA先前已被鉴定为功能性非编码RNA(http://www.johnlab.org/YB1)。我们鉴定出一种新的、丰富的、与Dicer1反义的3'-修饰短RNA(Shad1),它与YB-1共定位于P小体和应激颗粒。研究表明,Shad1的表达与YB-1的表达相关,其抑制会导致细胞增殖增加。此外,Shad1会影响癌症进展的其他预后标志物如DLX2和IGFBP2的表达。我们认为,对这些非编码RNA的检测可能有助于更好地理解前列腺癌的进展。